GlassScriptPhysician profile
Jeffrey S Hoffman
NPI 1104826122
$1,363.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $196 · 2021: $312 · 2022: $244.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.48 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.65 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $92.70 | 2019-2022 | |
| Allergan, INC. | $72.25 | 2019 | |
| Merck Sharp & Dohme LLC | $71.81 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.74 | 2019-2021 | |
| Janssen Biotech, INC. | $56.62 | 2019-2020 | |
| Braintree Laboratories, INC. | $43.02 | 2019-2022 | |
| Shionogi INC | $36.51 | 2019 | |
| Concordia Pharmaceuticals INC. | $33.12 | 2019 | |
| Redhill Biopharma INC. | $27.24 | 2020-2021 | |
| Gilead Sciences, INC. | $22.38 | 2019 | |
| Boston Scientific Corporation | $18.03 | 2021 | |
| Pfizer INC. | $16.98 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.65 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $11.79 | 2019 | |
| Daiichi Sankyo INC. | $10.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.